Milnacipran may increase the serotonergic activities of Normethadone.


ERGOTAMINE may increase the serotonergic activities of granisetron.


methylene blue may increase the serotonergic activities of Escitalopram.


methylene blue may increase the serotonergic activities of moclobemide.


cabergoline may increase the serotonergic activities of Tedizolid phosphate.


Levomilnacipran may increase the serotonergic activities of Ethylmorphine.


Lorcaserin may increase the serotonergic activities of dolasetron.


duloxetine may increase the serotonergic activities of Tedizolid phosphate.


paroxetine may increase the serotonergic activities of REMIFENTANIL.


methylene blue may increase the serotonergic activities of mirtazapine.


paroxetine may increase the serotonergic activities of pargyline.


methylene blue may increase the serotonergic activities of duloxetine.


nefazodone may increase the serotonergic activities of Pirlindole.


Milnacipran may increase the serotonergic activities of morphine.


methylene blue may increase the serotonergic activities of fluoxetine.


fluoxetine may increase the serotonergic activities of lithium ion.


rizatriptan may increase the serotonergic activities of Tedizolid phosphate.


methylene blue may increase the serotonergic activities of Levomilnacipran.


duloxetine may increase the serotonergic activities of tropisetron.


trimipramine may increase the serotonergic activities of Tedizolid phosphate.


Escitalopram may increase the serotonergic activities of Ketobemidone.


methylene blue may increase the serotonergic activities of L-tryptophan.


citalopram may increase the serotonergic activities of Pirlindole.


citalopram may increase the serotonergic activities of Toloxatone.


maprotiline may increase the serotonergic activities of L-tryptophan.


buspirone may increase the serotonergic activities of dolasetron.


Vilazodone may increase the serotonergic activities of buspirone.


dextromethorphan may increase the serotonergic activities of procarbazine.


Frovatriptan may increase the serotonergic activities of Tedizolid phosphate.


Phenelzine may increase the serotonergic activities of Palonosetron.


dextromethorphan may increase the serotonergic activities of Tedizolid phosphate.


amoxapine may increase the serotonergic activities of L-tryptophan.


Milnacipran may increase the serotonergic activities of pentazocine.


Frovatriptan may increase the serotonergic activities of granisetron.


duloxetine may increase the serotonergic activities of pargyline.


Almotriptan may increase the serotonergic activities of tropisetron.


paroxetine may increase the serotonergic activities of propoxyphene.


methylene blue may increase the serotonergic activities of trazodone.


duloxetine may increase the serotonergic activities of nalbuphine.


amoxapine may increase the serotonergic activities of Palonosetron.


Escitalopram may increase the serotonergic activities of DIHYDROCODEINE.


venlafaxine may increase the serotonergic activities of Methadyl acetate.


Escitalopram may increase the serotonergic activities of buspirone.


trazodone may increase the serotonergic activities of buspirone.


Escitalopram may increase the serotonergic activities of oxycodone.


citalopram may increase the serotonergic activities of REMIFENTANIL.


selegiline may increase the serotonergic activities of OXCARBAZEPINE.


moclobemide may increase the serotonergic activities of ondansetron.


clomipramine may increase the serotonergic activities of duloxetine.


Lorcaserin may increase the serotonergic activities of bupropion.


Escitalopram may increase the serotonergic activities of butorphanol.


clomipramine may increase the serotonergic activities of Palonosetron.


tranylcypromine may increase the serotonergic activities of cyclobenzaprine.


duloxetine may increase the serotonergic activities of Normethadone.


fluoxetine may increase the serotonergic activities of linezolid.


duloxetine may increase the serotonergic activities of Methadyl acetate.


amoxapine may increase the serotonergic activities of duloxetine.


Escitalopram may increase the serotonergic activities of L-tryptophan.


sertraline may increase the serotonergic activities of HEROIN.


citalopram may increase the serotonergic activities of DIPHENOXYLATE.


Phenelzine may increase the serotonergic activities of cyclobenzaprine.


selegiline may increase the serotonergic activities of Palonosetron.


citalopram may increase the serotonergic activities of granisetron.


amoxapine may increase the serotonergic activities of Toloxatone.


Levomilnacipran may increase the serotonergic activities of REMIFENTANIL.


Levomilnacipran may increase the serotonergic activities of Toloxatone.


Escitalopram may increase the serotonergic activities of Palonosetron.


imipramine may increase the serotonergic activities of duloxetine.


dextromethorphan may increase the serotonergic activities of tranylcypromine.


olanzapine may increase the serotonergic activities of Pirlindole.


olanzapine may increase the serotonergic activities of Toloxatone.


venlafaxine may increase the serotonergic activities of DIPHENOXYLATE.


fluvoxamine may increase the serotonergic activities of Pirlindole.


fluvoxamine may increase the serotonergic activities of Toloxatone.


amoxapine may increase the serotonergic activities of tropisetron.


Milnacipran may increase the serotonergic activities of pargyline.


linezolid may increase the serotonergic activities of ondansetron.


nefazodone may increase the serotonergic activities of levorphanol.


trazodone may increase the serotonergic activities of Palonosetron.


fluoxetine may increase the serotonergic activities of REMIFENTANIL.


bromocriptine may increase the serotonergic activities of ondansetron.


Eletriptan may increase the serotonergic activities of granisetron.


Levomilnacipran may increase the serotonergic activities of ALFENTANIL.


Escitalopram may increase the serotonergic activities of pentazocine.


Almotriptan may increase the serotonergic activities of granisetron.


clomipramine may increase the serotonergic activities of L-tryptophan.


nortriptyline may increase the serotonergic activities of Toloxatone.


sertraline may increase the serotonergic activities of Normethadone.


Levomilnacipran may increase the serotonergic activities of L-tryptophan.


imipramine may increase the serotonergic activities of Palonosetron.


VORTIOXETINE may increase the serotonergic activities of tropisetron.


VORTIOXETINE may increase the serotonergic activities of dolasetron.


Milnacipran may increase the serotonergic activities of ondansetron.


fluoxetine may increase the serotonergic activities of L-tryptophan.


cabergoline may increase the serotonergic activities of granisetron.


maprotiline may increase the serotonergic activities of Palonosetron.


dextromethorphan may increase the serotonergic activities of Palonosetron.


trimipramine may increase the serotonergic activities of tropisetron.


clomipramine may increase the serotonergic activities of linezolid.


Milnacipran may increase the serotonergic activities of codeine.


risperidone may increase the serotonergic activities of L-tryptophan.


Vilazodone may increase the serotonergic activities of tropisetron.


methylene blue may increase the serotonergic activities of cyclobenzaprine.


Vilazodone may increase the serotonergic activities of Tedizolid phosphate.


sumatriptan may increase the serotonergic activities of Palonosetron.


procarbazine may increase the serotonergic activities of cyclobenzaprine.


doxepin may increase the serotonergic activities of Pirlindole.


doxepin may increase the serotonergic activities of Toloxatone.


bromocriptine may increase the serotonergic activities of dolasetron.


fluoxetine may increase the serotonergic activities of ALFENTANIL.


Escitalopram may increase the serotonergic activities of DIPHENOXYLATE.


linezolid may increase the serotonergic activities of Tedizolid phosphate.


isocarboxazid may increase the serotonergic activities of tropisetron.


Milnacipran may increase the serotonergic activities of linezolid.


sumatriptan may increase the serotonergic activities of Tedizolid phosphate.


methylene blue may increase the serotonergic activities of citalopram.


Milnacipran may increase the serotonergic activities of buspirone.


zolmitriptan may increase the serotonergic activities of granisetron.


moclobemide may increase the serotonergic activities of granisetron.


sertraline may increase the serotonergic activities of SUFENTANIL.


Milnacipran may increase the serotonergic activities of dolasetron.


sertraline may increase the serotonergic activities of tropisetron.


Levomilnacipran may increase the serotonergic activities of DIHYDROCODEINE.


Milnacipran may increase the serotonergic activities of butorphanol.


Milnacipran may increase the serotonergic activities of furazolidone.


dihydroergotamine may increase the serotonergic activities of tropisetron.


rasagiline may increase the serotonergic activities of cyclobenzaprine.


amoxapine may increase the serotonergic activities of furazolidone.


desipramine may increase the serotonergic activities of Palonosetron.


methylene blue may increase the serotonergic activities of venlafaxine.


paroxetine may increase the serotonergic activities of linezolid.


Eletriptan may increase the serotonergic activities of tropisetron.


duloxetine may increase the serotonergic activities of dolasetron.


duloxetine may increase the serotonergic activities of butorphanol.


paroxetine may increase the serotonergic activities of DEZOCINE.


AMPHETAMINE may increase the serotonergic activities of cyclobenzaprine.


lithium ion may increase the serotonergic activities of L-tryptophan.


duloxetine may increase the serotonergic activities of furazolidone.


methylene blue may increase the serotonergic activities of amitriptyline.


citalopram may increase the serotonergic activities of Methadyl acetate.


Escitalopram may increase the serotonergic activities of HEROIN.


nefazodone may increase the serotonergic activities of buspirone.


procarbazine may increase the serotonergic activities of tropisetron.


procarbazine may increase the serotonergic activities of PHOLCODINE.


isocarboxazid may increase the serotonergic activities of granisetron.


trazodone may increase the serotonergic activities of Toloxatone.


Escitalopram may increase the serotonergic activities of nalbuphine.


nefazodone may increase the serotonergic activities of tropisetron.


isocarboxazid may increase the serotonergic activities of cyclobenzaprine.


selegiline may increase the serotonergic activities of ondansetron.


moclobemide may increase the serotonergic activities of L-tryptophan.


Levomilnacipran may increase the serotonergic activities of Palonosetron.


methadone may increase the serotonergic activities of tropisetron.


pargyline may increase the serotonergic activities of PHOLCODINE.


maprotiline may increase the serotonergic activities of tropisetron.


citalopram may increase the serotonergic activities of Normethadone.


naratriptan may increase the serotonergic activities of Tedizolid phosphate.


olanzapine may increase the serotonergic activities of nefazodone.


cabergoline may increase the serotonergic activities of tropisetron.


Escitalopram may increase the serotonergic activities of DEZOCINE.


trimipramine may increase the serotonergic activities of pargyline.


venlafaxine may increase the serotonergic activities of DEZOCINE.


Levomilnacipran may increase the serotonergic activities of Ketobemidone.


duloxetine may increase the serotonergic activities of Palonosetron.


tranylcypromine may increase the serotonergic activities of PHOLCODINE.


lithium ion may increase the serotonergic activities of Palonosetron.


Milnacipran may increase the serotonergic activities of Ethylmorphine.


dextromethorphan may increase the serotonergic activities of L-tryptophan.


granisetron may increase the serotonergic activities of L-tryptophan.


sertraline may increase the serotonergic activities of DEZOCINE.


clomipramine may increase the serotonergic activities of tropisetron.


citalopram may increase the serotonergic activities of ondansetron.


Escitalopram may increase the serotonergic activities of dolasetron.


methylene blue may increase the serotonergic activities of pargyline.


duloxetine may increase the serotonergic activities of ALFENTANIL.


Escitalopram may increase the serotonergic activities of tropisetron.


oxycodone may increase the serotonergic activities of L-tryptophan.


Levomilnacipran may increase the serotonergic activities of pentazocine.


Levomilnacipran may increase the serotonergic activities of butorphanol.


Levomilnacipran may increase the serotonergic activities of furazolidone.


citalopram may increase the serotonergic activities of Palonosetron.


Pirlindole may increase the serotonergic activities of L-tryptophan.


fluvoxamine may increase the serotonergic activities of furazolidone.


procarbazine may increase the serotonergic activities of granisetron.


trimipramine may increase the serotonergic activities of furazolidone.


Levomilnacipran may increase the serotonergic activities of dolasetron.


linezolid may increase the serotonergic activities of dolasetron.


sertraline may increase the serotonergic activities of L-tryptophan.


fluoxetine may increase the serotonergic activities of furazolidone.


doxepin may increase the serotonergic activities of linezolid.


protriptyline may increase the serotonergic activities of Toloxatone.


fluoxetine may increase the serotonergic activities of nalbuphine.


bupropion may increase the serotonergic activities of L-tryptophan.


Dothiepin may increase the serotonergic activities of procarbazine.


Levomilnacipran may increase the serotonergic activities of levorphanol.


citalopram may increase the serotonergic activities of dolasetron.


trimipramine may increase the serotonergic activities of Palonosetron.


citalopram may increase the serotonergic activities of butorphanol.


rasagiline may increase the serotonergic activities of L-tryptophan.


Levomilnacipran may increase the serotonergic activities of buprenorphine.


Milnacipran may increase the serotonergic activities of tropisetron.


dextromethorphan may increase the serotonergic activities of fluoxetine.


trimipramine may increase the serotonergic activities of duloxetine.


dextromethorphan may increase the serotonergic activities of duloxetine.


methylene blue may increase the serotonergic activities of nefazodone.


trazodone may increase the serotonergic activities of furazolidone.


metoclopramide may increase the serotonergic activities of L-tryptophan.


naratriptan may increase the serotonergic activities of tropisetron.


methylene blue may increase the serotonergic activities of doxepin.


zolmitriptan may increase the serotonergic activities of L-tryptophan.


Levomilnacipran may increase the serotonergic activities of HEROIN.


Milnacipran may increase the serotonergic activities of REMIFENTANIL.


amoxapine may increase the serotonergic activities of pargyline.


duloxetine may increase the serotonergic activities of pentazocine.


fluvoxamine may increase the serotonergic activities of buspirone.


Milnacipran may increase the serotonergic activities of hydromorphone.


venlafaxine may increase the serotonergic activities of Pirlindole.


paroxetine may increase the serotonergic activities of DIPHENOXYLATE.


rizatriptan may increase the serotonergic activities of Palonosetron.


paroxetine may increase the serotonergic activities of buspirone.


duloxetine may increase the serotonergic activities of buspirone.


Normethadone may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


oxymorphone may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


lithium ion may increase the excretion rate of SODIUM BICARBONATE which could result in a lower serum level and potentially a reduction in efficacy.


SUFENTANIL may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


Ethylmorphine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


morphine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


acemetacin may increase the excretion rate of furosemide which could result in a lower serum level and potentially a reduction in efficacy.


REMIFENTANIL may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


DEZOCINE may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


levorphanol may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


codeine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


ALFENTANIL may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


butorphanol may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


methadone may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


hydromorphone may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


buprenorphine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


HEROIN may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


pentazocine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


lithium ion may increase the excretion rate of sodium chloride which could result in a lower serum level and potentially a reduction in efficacy.


HYDROCODONE may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


DIPHENOXYLATE may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


meperidine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


Ketobemidone may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


propoxyphene may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


Methadyl acetate may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


nalbuphine may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


DIHYDROCODEINE may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


Tapentadol may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


Tramadol may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


oxycodone may increase the excretion rate of AMMONIUM CHLORIDE which could result in a lower serum level and potentially a reduction in efficacy.


The risk or severity of bleeding can be increased when Betrixaban is combined with BENZYDAMINE.


The risk or severity of bleeding can be increased when Betrixaban is combined with alclofenac.


The risk or severity of bleeding can be increased when Apixaban is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Olopatadine.


The risk or severity of bleeding can be increased when Betrixaban is combined with ADAPALENE.


The risk or severity of bleeding can be increased when Betrixaban is combined with sulindac.


The risk or severity of bleeding can be increased when Betrixaban is combined with citalopram.


The risk or severity of bleeding can be increased when Betrixaban is combined with floctafenine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Sodium citrate.


The risk or severity of bleeding can be increased when Betrixaban is combined with chloroquine.


The risk or severity of bleeding can be increased when Betrixaban is combined with epirizole.


The risk or severity of bleeding can be increased when Betrixaban is combined with mycophenolic acid.


The risk or severity of bleeding can be increased when Betrixaban is combined with nefazodone.


The risk or severity of bleeding can be increased when Betrixaban is combined with Etoricoxib.


The risk or severity of bleeding can be increased when Betrixaban is combined with carprofen.


The risk or severity of bleeding can be increased when EDOXABAN is combined with acemetacin.


The risk or severity of bleeding can be increased when dicumarol is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with diclofenac.


The risk or severity of bleeding can be increased when Betrixaban is combined with oxaprozin.


The risk or severity of bleeding can be increased when Betrixaban is combined with antipyrine.


The risk or severity of bleeding can be increased when Betrixaban is combined with tolmetin.


The risk or severity of bleeding can be increased when Betrixaban is combined with fenbufen.


The risk or severity of bleeding can be increased when Betrixaban is combined with ETOFENAMATE.


The risk or severity of bleeding can be increased when Betrixaban is combined with CLONIXIN.


The risk or severity of bleeding can be increased when Betrixaban is combined with tolfenamic acid.


The risk or severity of bleeding can be increased when Betrixaban is combined with Droxicam.


The risk or severity of bleeding can be increased when Betrixaban is combined with Loxoprofen.


The risk or severity of bleeding can be increased when Betrixaban is combined with niflumic acid.


The risk or severity of bleeding can be increased when PENTAERYTHRITOL TETRANITRATE is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Levomilnacipran.


The risk or severity of bleeding can be increased when Betrixaban is combined with ZILEUTON.


The risk or severity of bleeding can be increased when phenindione is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with etodolac.


The risk or severity of bleeding can be increased when argatroban is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Pimecrolimus.


The risk or severity of bleeding can be increased when Betrixaban is combined with zaltoprofen.


The risk or severity of bleeding can be increased when Betrixaban is combined with Aceclofenac.


The risk or severity of bleeding can be increased when Betrixaban is combined with SERATRODAST.


The risk or severity of bleeding can be increased when Betrixaban is combined with oxyphenbutazone.


The risk or severity of bleeding can be increased when pentosan polysulfate is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Apixaban is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with ketoprofen.


The risk or severity of bleeding can be increased when Rivaroxaban is combined with homoharringtonine.


The risk or severity of bleeding can be increased when PENTAERYTHRITOL TETRANITRATE is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Nepafenac.


The risk or severity of bleeding can be increased when Betrixaban is combined with Magnesium salicylate.


The risk or severity of bleeding can be increased when PHENPROCOUMON is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Salsalate.


The risk or severity of bleeding can be increased when Betrixaban is combined with Naftifine.


The risk or severity of bleeding can be increased when Betrixaban is combined with meclofenamic acid.


The risk or severity of bleeding can be increased when Betrixaban is combined with leflunomide.


The risk or severity of bleeding can be increased when Betrixaban is combined with indomethacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with mesalamine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Teriflunomide.


The risk or severity of bleeding can be increased when EDOXABAN is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with sulfasalazine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Choline magnesium trisalicylate.


The risk or severity of bleeding can be increased when Fondaparinux is combined with homoharringtonine.


The risk or severity of bleeding can be increased when 3,4-Dihydroxybenzaldehyde is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Icatibant.


The risk or severity of bleeding can be increased when Betrixaban is combined with Propacetamol.


The risk or severity of bleeding can be increased when Betrixaban is combined with celecoxib.


The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with mefenamic acid.


The risk or severity of bleeding can be increased when Fondaparinux is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Olsalazine.


The risk or severity of bleeding can be increased when Betrixaban is combined with aspirin.


The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with sertraline.


The risk or severity of bleeding can be increased when Betrixaban is combined with NAPROXEN.


The risk or severity of bleeding can be increased when Betrixaban is combined with BALSALAZIDE.


The risk or severity of bleeding can be increased when Rivaroxaban is combined with acemetacin.


The risk or severity of bleeding can be increased when EDTA is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Apremilast.


The risk or severity of bleeding can be increased when Bivalirudin is combined with homoharringtonine.


The risk or severity of bleeding can be increased when ACENOCOUMAROL is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with flurbiprofen.


The risk or severity of bleeding can be increased when Betrixaban is combined with paroxetine.


The risk or severity of bleeding can be increased when citric acid is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Escitalopram.


The risk or severity of bleeding can be increased when Betrixaban is combined with suprofen.


The risk or severity of bleeding can be increased when Betrixaban is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Lornoxicam.


The risk or severity of bleeding can be increased when phenindione is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with azelastine.


The risk or severity of bleeding can be increased when Betrixaban is combined with diflunisal.


The risk or severity of bleeding can be increased when Ximelagatran is combined with homoharringtonine.


The risk or severity of bleeding can be increased when EDTA is combined with acemetacin.


The risk or severity of bleeding can be increased when Ximelagatran is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Milnacipran.


The risk or severity of bleeding can be increased when Betrixaban is combined with fluvoxamine.


The risk or severity of bleeding can be increased when Betrixaban is combined with Masoprocol.


The risk or severity of bleeding can be increased when Betrixaban is combined with PIRFENIDONE.


The risk or severity of bleeding can be increased when pentosan polysulfate is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with fenoprofen.


The risk or severity of bleeding can be increased when Betrixaban is combined with ketorolac.


The risk or severity of bleeding can be increased when Betrixaban is combined with nabumetone.


The risk or severity of bleeding can be increased when Betrixaban is combined with tenoxicam.


The risk or severity of bleeding can be increased when Betrixaban is combined with mycophenolate mofetil.


The risk or severity of bleeding can be increased when Betrixaban is combined with Lumiracoxib.


The risk or severity of bleeding can be increased when warfarin is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with resveratrol.


The risk or severity of bleeding can be increased when citric acid is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with salicylamide.


The risk or severity of bleeding can be increased when warfarin is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with venlafaxine.


The risk or severity of bleeding can be increased when Bivalirudin is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with salicylic acid.


The risk or severity of bleeding can be increased when argatroban is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with nimesulide.


The risk or severity of bleeding can be increased when PHENPROCOUMON is combined with homoharringtonine.


The risk or severity of bleeding can be increased when dicumarol is combined with homoharringtonine.


The risk or severity of bleeding can be increased when Betrixaban is combined with tiaprofenic acid.


The risk or severity of bleeding can be increased when Betrixaban is combined with duloxetine.


The risk or severity of bleeding can be increased when 3,4-Dihydroxybenzaldehyde is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with fluoxetine.


The risk or severity of bleeding can be increased when ACENOCOUMAROL is combined with acemetacin.


The risk or severity of bleeding can be increased when Betrixaban is combined with Rivaroxaban.


The risk or severity of bleeding can be increased when Betrixaban is combined with ibuprofen.


cinoxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


clotrimazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of MAGNESIUM SULFATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


benzoic acid can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


L-thyroxine can cause a decrease in the absorption of raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


sulconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimetrexate can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sertaconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


clotrimazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of dexlansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


rapamycin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of MAGNESIUM SULFATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


cefuroxime can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


terconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of doxepin resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pazopanib can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Miltefosine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pazopanib can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Butoconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of rabeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


PHENPROCOUMON can cause a decrease in the absorption of Lixisenatide resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


pentamidine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cholic acid can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Caspofungin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


ACENOCOUMAROL can cause a decrease in the absorption of Lixisenatide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


butenafine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cholic acid can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


itraconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Posaconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Micafungin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nitrendipine can cause a decrease in the absorption of ursodiol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pazopanib can cause a decrease in the absorption of Asenapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


hexetidine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cyclosporin A can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of lansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


CICLOPIROX can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


cyclosporin A can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


oxiconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of pantoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of dexlansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


benzoic acid can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


rapamycin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of pantoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Caspofungin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of doxepin resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


NATAMYCIN can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Anidulafungin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


EFINACONAZOLE can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


ketoconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


MORICIZINE can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of Esomeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


THYMOL can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Atazanavir can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


methylene blue can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of doxepin resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Sodium phosphate monobasic can cause a decrease in the absorption of FERRIC CITRATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of epinastine resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of FERRIC PYROPHOSPHATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


tioconazole can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of olanzapine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Aceprometazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of omeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of cimetidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimetrexate can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


minocycline can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


nystatin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


cinoxacin can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


5-Fluorocytosine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


periciazine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Delavirdine can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


promethazine can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


miconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.


terconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


haloprogin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


trifluoperazine can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


lincomycin can cause a decrease in the absorption of KAOLIN resulting in a reduced serum concentration and potentially a decrease in efficacy.


sparfloxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


salicylic acid can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of Esomeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


triflupromazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Artemether can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Sevelamer resulting in a reduced serum concentration and potentially a decrease in efficacy.


trimeprazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


promazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


mycophenolic acid can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of calcium lactate resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


amphotericin b can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


perphenazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Naftifine can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


CEFPODOXIME can cause a decrease in the absorption of ranitidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


estramustine can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Esomeprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


isoniazid can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


pentamidine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


cerulenin can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


prochlorperazine can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Thioproperazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Levomepromazine can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.


lipoic acid can cause a decrease in the absorption of FERRIC PYROPHOSPHATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Naftifine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


mesoridazine can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


terbinafine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of famotidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


chlortetracycline can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


FLUPHENAZINE can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


nalidixic acid can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Magaldrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of Calcium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.


allopurinol can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


fleroxacin can cause a decrease in the absorption of Calcium acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Anidulafungin can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


LEVOFLOXACIN can cause a decrease in the absorption of MAGNESIUM HYDROXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of SODIUM BICARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of MAGNESIUM OXIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


chloroxine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


enoxacin can cause a decrease in the absorption of Glubionate calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Almasilate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


norfloxacin can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gatifloxacin can cause a decrease in the absorption of Calcium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.


demeclocycline can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Trovafloxacin can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dasatinib can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


butenafine can cause a decrease in the absorption of Sucralfate resulting in a reduced serum concentration and potentially a decrease in efficacy.


trientine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.


THYMOL can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


ROSOXACIN can cause a decrease in the absorption of CALCIUM CHLORIDE resulting in a reduced serum concentration and potentially a decrease in efficacy.


thioridazine can cause a decrease in the absorption of Magnesium trisilicate resulting in a reduced serum concentration and potentially a decrease in efficacy.


Gemifloxacin can cause a decrease in the absorption of CALCIUM GLUCONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Iron sucrose can cause a decrease in the absorption of lansoprazole resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC CITRATE can cause a decrease in the absorption of Aluminium resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pefloxacin can cause a decrease in the absorption of Bismuth subcitrate potassium resulting in a reduced serum concentration and potentially a decrease in efficacy.


FERRIC PYROPHOSPHATE can cause a decrease in the absorption of nizatidine resulting in a reduced serum concentration and potentially a decrease in efficacy.


Pazopanib can cause a decrease in the absorption of ROXATIDINE ACETATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Isoconazole can cause a decrease in the absorption of didanosine resulting in a reduced serum concentration and potentially a decrease in efficacy.


doxycycline can cause a decrease in the absorption of CALCIUM CARBONATE resulting in a reduced serum concentration and potentially a decrease in efficacy.


Dipotassium hydrogen phosphate can cause a decrease in the absorption of Trometamol resulting in a reduced serum concentration and potentially a decrease in efficacy.


mequitazine can cause a decrease in the absorption of Aluminium hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.